Protara Therapeutics Inc
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous cholin… Read more
Protara Therapeutics Inc (TARA) - Total Assets
Latest total assets as of September 2025: $144.64 Million USD
Based on the latest financial reports, Protara Therapeutics Inc (TARA) holds total assets worth $144.64 Million USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Protara Therapeutics Inc - Total Assets Trend (2012–2024)
This chart illustrates how Protara Therapeutics Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Protara Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Protara Therapeutics Inc's total assets of $144.64 Million consist of 94.9% current assets and 5.1% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 89.7% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $3.25 Million | 1.8% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2012–2024)
This chart illustrates how Protara Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Protara Therapeutics Inc's current assets represent 94.9% of total assets in 2024, a decrease from 99.0% in 2012.
- Cash Position: Cash and equivalents constituted 89.7% of total assets in 2024, up from 31.0% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, an increase from 0.0% in 2012.
- Asset Diversification: The largest asset category is intangible assets at 1.8% of total assets.
Protara Therapeutics Inc Competitors by Total Assets
Key competitors of Protara Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
ESSA Pharma Inc
NASDAQ:EPIX
|
USA | $110.50 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Protara Therapeutics Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Protara Therapeutics Inc generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Protara Therapeutics Inc is currently not profitable relative to its asset base.
Protara Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 13.69 | 9.85 | 58.13 |
| Quick Ratio | 13.69 | 9.85 | 58.13 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $125.73 Million | $ 76.44 Million | $ 166.52 Million |
Protara Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Protara Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.33 |
| Latest Market Cap to Assets Ratio | 0.98 |
| Asset Growth Rate (YoY) | 129.8% |
| Total Assets | $181.45 Million |
| Market Capitalization | $178.23 Million USD |
Valuation Analysis
Near Book Valuation: The market values Protara Therapeutics Inc's assets close to their book value ( 0.98x), suggesting investors view the company's assets at approximately fair value.
Rapid Asset Growth: Protara Therapeutics Inc's assets grew by 129.8% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Protara Therapeutics Inc (2012–2024)
The table below shows the annual total assets of Protara Therapeutics Inc from 2012 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $181.45 Million | +129.82% |
| 2023-12-31 | $78.95 Million | -30.31% |
| 2022-12-31 | $113.29 Million | -34.36% |
| 2021-12-31 | $172.60 Million | -15.04% |
| 2020-12-31 | $203.16 Million | +2812.65% |
| 2019-12-31 | $6.97 Million | -70.35% |
| 2018-12-31 | $23.52 Million | -46.52% |
| 2017-12-31 | $43.98 Million | +1.05% |
| 2016-12-31 | $43.52 Million | -35.56% |
| 2015-12-31 | $67.54 Million | -20.35% |
| 2014-12-31 | $84.80 Million | +1398.46% |
| 2013-12-31 | $5.66 Million | -27.28% |
| 2012-12-31 | $7.78 Million | -- |